POTOMAC, Md.–(BUSINESS WIRE)–India Globalization Capital, Inc. (the “Firm”) (NYSE American: IGC) introduced at present that on July 20, 2021, america Patent and Trademark Workplace (“USPTO”) issued a patent (#11,065,225) for the remedy of Alzheimer’s illness entitled “Extremely-Low dose THC as a possible therapeutic and prophylactic agent for Alzheimer’s Illness.”
The unique patent utility was initiated by the College of South Florida (“USF”) and filed on August 1, 2016. On Could 25, 2017, IGC entered into an unique license settlement with USF with respect to the patent utility and the related analysis carried out on Alzheimer’s illness.
The granted patent pertains to IGC’s proprietary formulation supposed to help within the remedy of people dwelling with Alzheimer’s illness. IGC’s proprietary formulation, IGC-AD1, is the topic of the Firm’s previously-disclosed Section 1 medical trial. The Firm just lately introduced the completion of Cohort 3 in its placebo-controlled A number of Ascending Dose (MAD) part 1 trial for establishing security and tolerability of IGC-AD1 that makes use of THC on sufferers affected by Alzheimer’s illness.
This press launch incorporates forward-looking statements inside the which means of Part 21E of the Securities Change Act of 1934. These forward-looking statements are primarily based largely on IGC’s expectations and are topic to a number of dangers and uncertainties, sure of that are past IGC’s management. Precise outcomes may differ materially from these forward-looking statements on account of, amongst different elements, the Firm’s failure or incapability to commercialise a number of of the Firm’s merchandise or applied sciences, together with the investigational new drug or formulation described on this launch, or failure to acquire FDA approval for the investigational new drug; testing outcomes from human medical trials that might not be favorable or as anticipated; basic financial situations which can be much less favorable than anticipated, together with on account of the continuing COVID-19 pandemic; the FDA’s basic place relating to cannabis- and hemp-based merchandise; and different elements, lots of that are mentioned in IGC’s SEC filings. IGC incorporates by reference the human trial disclosures and Danger Elements recognized in its Annual Report on Type 10-Ok filed with the SEC on June 14, 2021, as if absolutely included and restated herein. Contemplating these dangers and uncertainties, there could be no assurance that the forward-looking info contained on this launch will happen.
India Globalization Capital, Inc. (IGC) engages within the growth of cannabinoid-based therapies for indications akin to Alzheimer’s illness and ache. It operates in two traces of enterprise, Infrastructure and Life Sciences and is headquartered in Potomac, MD.